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ABSTRACT 44 
Lipid overload in obesity and type 2 diabetes is associated with adipocyte dysfunction, 45 
inflammation, macrophage infiltration and decreased fatty acid oxidation (FAO). Here 46 
we report that the expression of carnitine palmitoyltransferase 1A (CPT1A), the rate-47 
limiting enzyme in mitochondrial FAO, is higher in human adipose tissue macrophages 48 
than in adipocytes and that it is differentially expressed in visceral vs. subcutaneous 49 
adipose tissue both in an obese and a type 2 diabetes cohort. These observations led us 50 
to further investigate the potential role of CPT1A in adipocytes and macrophages. We 51 
expressed CPT1AM, a permanently active mutant form of CPT1A, in 3T3-L1 CARΔ1 52 
adipocytes and RAW 264.7 macrophages through adenoviral infection. Enhanced FAO 53 
in palmitate-incubated adipocytes and macrophages reduced triglyceride content and 54 
inflammation, improved insulin sensitivity in adipocytes and reduced ER stress and 55 
ROS damage in macrophages. We conclude that increasing FAO in adipocytes and 56 
macrophages improves palmitate-induced derangements. This indicates that enhancing 57 
FAO in metabolically relevant cells such as adipocytes and macrophages may be a 58 
promising strategy for the treatment of chronic inflammatory pathologies such as 59 
obesity and type 2 diabetes. 60 
61 
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binding transcription factor 1; SVF, stromal-vascular fraction; TLR-4, toll-like receptor-76 
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INTRODUCTION 82 
Obesity has reached epidemic proportions worldwide, leading to severe 83 
associated pathologies such as insulin resistance, type 2 diabetes (T2D), cardiovascular 84 
disease, Alzheimer’s disease, hypertension, hypercholesterolemia, hypertriglyceridemia, 85 
non-alcoholic fatty liver disease (NAFLD), arthritis, asthma, and certain forms of 86 
cancer (12).  87 
Over the last two decades adipose tissue has gained crucial importance in the 88 
mechanisms involved in obesity-related disorders. The energy-storing white adipose 89 
tissue (WAT) is well vascularized and contains adipocytes, connective tissue and 90 
numerous immune cells such as macrophages, T and B cells, mast cells and neutrophils 91 
that infiltrate and increase their presence during obesity (22). Macrophages were the 92 
first immune cells reported to participate in obesity-induced insulin resistance (56). This 93 
highlights their pathological role in adipose tissue in addition to their traditional 94 
involvement in tissue repair and in response to dead and dying adipocytes (5, 14). Fat is 95 
an active endocrine tissue that secretes hormones such as leptin, adiponectin or resistin 96 
and inflammatory cytokines such as TNF-α, IL-6, IL-1β, etc. in response to several 97 
stimuli. It is therefore a complex organ controlling energy expenditure, appetite, insulin 98 
sensitivity, endocrine and reproductive functions, inflammation and immunity (53). 99 
The pathophysiology of obesity-induced insulin resistance has been attributed to 100 
ectopic fat deposition (39), increased inflammation and ER stress (16, 42), adipose 101 
tissue hypoxia (15) and mitochondrial dysfunction (32), and impaired adipocyte 102 
expansion and angiogenesis (50, 51, 54). In obesity, fatty acids (FA) together with other 103 
stimuli such as ceramide, various PKC isoforms, proinflammatory cytokines and ROS 104 
and ER stresses activate JNK, NF-κB, RAGE and TLR pathways both in adipocytes and 105 
macrophages triggering inflammation and insulin resistance (43). 106 
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Strenuous efforts are being made by the research community to elucidate the 107 
mechanisms involved in the pathophysiology of obesity-related disorders. However, an 108 
alternative strategy could be to act upstream by preventing the accumulation of lipids 109 
and the progression of obesity. In addition to reducing caloric intake, a potential 110 
effective approach to combat obesity would be to increase energy expenditure in key 111 
metabolic organs, such as adipose tissue. Obese individuals and those with T2D are 112 
known to have lower fatty acid oxidation (FAO) rates and lower electron transport chain 113 
activity in muscle (17, 19, 37) together with higher glycolytic capacities and enhanced 114 
cellular FA uptake compared to non-obese and non-diabetic individuals (44). Thus, any 115 
strategy able to eliminate the excess of lipids found in obesity could be beneficial for 116 
health. Lipid levels can be reduced by inhibiting synthesis, transport or by increasing 117 
oxidation: here we focus on the latter. 118 
Malonyl-CoA, derived from glucose metabolism and the first intermediate in 119 
lipogenesis, regulates FAO by inhibiting carnitine palmitoyltransferase 1 (CPT1). This 120 
makes CPT1 the rate-limiting step in mitochondrial FA β-oxidation. Thus, in high-121 
energy conditions malonyl-CoA inhibits oxidation diverting FAs fate into TG 122 
accumulation. There are three CPT1 isoforms, with differential tissue expression: 123 
CPT1A (liver, kidney, intestine, pancreas, ovary and mouse and human WAT), CPT1B 124 
(brown adipose tissue, skeletal muscle, heart and rat and human WAT), and CPT1C 125 
(brain and testis) (2, 36). The fact that CPT1 controls FAO makes it a very attractive 126 
target to reduce lipid levels and fight against obesity and T2D. In spite of their excess 127 
fat, obese individuals have reduced visceral WAT CPT1 mRNA and protein levels (20). 128 
This prompted our group and others to overexpress CPT1 in liver (26, 30, 46), muscle 129 
(4, 33, 41), and white adipocytes (9), which led to a decrease in TG content and an 130 
improvement in insulin sensitivity.  131 
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Here we showed that CPT1A expression was higher in human adipose tissue 132 
macrophages than in mature adipocytes and that it was differentially expressed in 133 
visceral vs. subcutaneous adipose tissue. To further investigate the role of CPT1A in 134 
both adipocytes and macrophages we used a permanently active mutant form of 135 
CPT1A, CPT1AM, which is insensitive to its inhibitor malonyl-CoA (27), to achieve 136 
continuous oxidation of lipids. When cells were incubated with palmitate to mimic 137 
obesity, CPT1AM restored most of the palmitate-induced imbalances. An increase in 138 
FAO in adipocytes and macrophages reduced TG content and inflammatory levels, 139 
improved insulin sensitivity in adipocytes, and reduced endoplasmic reticulum (ER) 140 
stress and ROS damage in macrophages.  141 
142 
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MATERIALS AND METHODS 143 
Human cohorts 144 
Selection of patients 145 
Adipose tissue was selected from an adipose tissue biobank collection of the University 146 
Hospital Joan XXII (Tarragona, Spain). All subjects were of Caucasian origin and 147 
reported that their body weight had been stable for at least 3 months before the study. 148 
They had no systemic disease other than obesity or T2D, and all had been free of any 149 
infections in the previous month before the study. Liver and renal diseases were 150 
specifically excluded by biochemical work-up. Appropriate Institutional Review Board 151 
approval and adequate biobank informed consent was obtained from all participants. 152 
Bio-banking samples included plasma, total and fractionated adipose tissue from 153 
subcutaneous and visceral origin. All patients had fasted overnight before collection of 154 
blood and adipose tissue samples. Visceral adipose tissue (VAT) and subcutaneous 155 
adipose tissue (SAT) samples were obtained during surgical procedures that included 156 
laparoscopic surgery for hiatus hernia repair or cholecystectomy. Samples were selected 157 
according stratification by age, gender and BMI and grouped into two cohorts: 158 
Obesity cohort. Subjects were classified by BMI according to the World Health 159 
Organization criteria (WHO, 2000). The study included 19 lean, 28 overweight, and 15 160 
obese non-diabetic subjects, matched for age and gender (Table 1). 161 
Type 2 diabetes cohort. Patients were classified as having T2D according to the 162 
American Diabetes Association criteria (1997). Variability in metabolic control was 163 
assessed by stable glycated hemoglobin A1c (HbA1c) values during the previous 6 164 
months. Gathering these criteria, there were 11 T2D subjects. As a control group, we 165 
selected 36 subjects without diabetes from the obesity cohort, matched for age, BMI and 166 
gender (Table 2). No patient was being treated with thiazolidinedione.  167 
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 168 
Anthropometric measurements 169 
Height was measured to the nearest 0.5 cm and body weight to the nearest 0.1 kg. BMI 170 
was calculated as weight (kilograms) divided by height (meters) squared. Waist 171 
circumference was measured midway between the lowest rib margin and the iliac crest.  172 
 173 
Collection and processing of human samples 174 
Samples from VAT (visceral adipose tissue, omental) and SAT (subcutaneous adipose 175 
tissue, anterior abdominal wall) from the same individual were obtained during 176 
abdominal elective surgical procedures (cholecystectomy or surgery for abdominal 177 
hernia). All patients had fasted overnight, at least 12 hours before surgical procedure. 178 
Blood samples were collected before the surgical procedure from the antecubital vein, 179 
20 ml of blood with EDTA (1mg/ml) and 10 ml of blood in silicone tubes. 15 ml of 180 
collected blood was used for the separation of plasma. Plasma samples were stored at -181 
80ºC until analytical measurements were performed. 5 ml of blood with EDTA was 182 
used for the determination of HbA1c. Adipose tissue samples were collected, washed in 183 
PBS, immediately frozen in liquid N2 and stored at -80°C.  184 
 185 
Adipose tissue fractionation 186 
Adipose tissue biopsies were immediately processed. The adipose tissue was finely 187 
diced into small pieces (10-30 mg), washed in PBS and incubated in Medium 199 (Life 188 
Technologies) supplemented with 4% BSA plus 2 mg/ml of collagenase Type I (Sigma) 189 
for 1 h in a shaking water bath at 37ºC. After digestion, mature adipocytes (ADI) were 190 
separated from tissue matrix by filtration through a 200 μm mesh fabric (Spectrum 191 
Laboratories). The filtrated solution was centrifuged for 5 min at 1500xg. The mature 192 
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adipocytes were removed from the top layer and the SVF cells remained in the pellet. 193 
Cells were washed 4 times in PBS and processed for RNA and protein extraction. 194 
 195 
Analytical methods 196 
Glucose, cholesterol and TG plasma levels were determined in an auto-analyser 197 
(Hitachi 737, Boehringer Mannheim) using the standard enzyme methods. High-density 198 
lipoprotein (HDL) cholesterol was quantified after precipitation with polyethylene 199 
glycol at room temperature (PEG-6000). Plasma insulin was determined by 200 
radioimmunoassay (Coat-A-Count insulin; Diagnostic Products Corp.). Non-esterified 201 
Free Fat Acid (NEFA) serum levels were determined in an autoanalyser (Advia 1200, 202 
Siemens AG) using an enzymatic method developed by Wako Chemicals. Plasma 203 
glycerol levels were analyzed by using a free glycerol determination kit, a quantitative 204 
enzymatic determination assay (Sigma-Aldrich Corp.). Intra- and interassay CV were 205 
less than 6% and less than 9.1%, respectively. The degree of insulin resistance was 206 
determined by the homeostasis model assessment (HOMA), as [glucose (mmol/l) x 207 
insulin (mIU/l)]/22.5](24). 208 
 209 
Immunohistochemistry 210 
Five-micron sections of formalin-fixed paraffin-embedded adipose tissue were 211 
deparaffinised and rehydrated prior to antigen unmasking by boiling in 1mM EDTA, 212 
pH 8. Sections were blocked in normal serum and incubated overnight with rabbit anti-213 
CPT1A (Sigma-Aldrich) at 1:50 dilution. Secondary antibody staining was performed 214 
using the VECTASTAIN ABC kit (Vector Laboratories, Inc.) and detected with 215 
diaminobenzidine (DAB, Vector Laboratories, Inc.). Sections were counterstained with 216 
hematoxylin prior to dehydration and coverslip placement, and examined under a Nikon 217 
 11
Eclipse 90i microscope. As a negative control, the procedure was performed in the 218 
absence of primary antibody. 219 
 220 
Immunofluorescence 221 
Five-micron sections of formalin-fixed paraffin-embedded adipose tissue were blocked 222 
in normal serum and incubated overnight with rabbit anti-CPT1A antibody (Sigma-223 
Aldrich) at 1:50 dilution, and with mouse anti-CD68 (Santa Cruz Biotechnology, Inc.) 224 
at 1:50 dilution, washed, and visualized using Alexa Fluor 546 goat anti-rabbit, and 225 
Alexa Fluor 488 goat anti-mouse antibodies, respectively (1:500; Molecular Probes 226 
Inc.). The slides were counterstained with DAPI (4,6-diamidino-2-phenylindole) to 227 
reveal nuclei and were examined under a Nikon Eclipse 90i fluorescent microscope. As 228 
a negative control, the assay was performed in the absence of primary antibody. 229 
 230 
Materials 231 
Sodium palmitate, sodium oleate, BSA and L-carnitine hydrochloride were purchased 232 
from Sigma Aldrich. DMEM, FBS and Penicillin/Streptomycin mixture were purchased 233 
from Life Technologies. 234 
 235 
Cell culture 236 
Murine 3T3-L1 CARΔ1 preadipocytes, kindly given by Dr. Orlicky (Department of 237 
Pathology, UCHSC at Fitzsimons, Aurora, CO, USA), were cultured and differentiated 238 
into mature adipocytes following the published protocol (31). Mature adipocytes were 239 
used for experiments at day 8 post-differentiation. Murine RAW 264.7 macrophages 240 
were obtained from ATCC and were maintained in DMEM supplemented with 10% 241 
heat-inactivated FBS and 1% penicillin/streptomycin mixture. Simpson-Golabi-Behmel 242 
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Syndrome (SGBS) human cells were cultured and differentiated to adipocytes as 243 
previously described (55). 244 
 245 
Adenovirus (Ad) infection 246 
At day 8 of differentiation, 3T3-L1 CARΔ1 cells were infected with AdGFP (100 moi) 247 
and AdCPT1AM (13) (100 moi) for 24 h in serum-free DMEM and then the medium 248 
was replaced with complete DMEM for additional 24 h. RAW 264.7 macrophages were 249 
infected with AdGFP (100 moi) and AdCPT1AM (100 moi) for 2 h in serum-free 250 
DMEM and then replaced with complete medium for additional 72 h. The adenovirus 251 
infection efficiency was assessed in AdGFP-infected cells (Figure 3A and B). The same 252 
batch of adenoviruses stored in 50μl aliquots was used throughout the experiments. 253 
 254 
Fatty acid (FA) treatment 255 
Sodium palmitate was conjugated with FA-free BSA in a 5:1 ratio to yield a stock 256 
solution of 2.5mM (41). Cells were incubated with 0.3 mM or 1 mM of this solution for 257 
24 h (3T3-L1 CARΔ1 adipocytes) or 0.3 mM, 0.5 mM or 0.75 mM for 24, 8 or 18 h 258 
(RAW 264.7 macrophages), respectively. 259 
 260 
Adipocyte and macrophage viability 261 
3T3-L1 CARΔ1 adipocytes and RAW 264.7 macrophages were infected as previously 262 
described and incubated for 24h with 1mM or 0.3mM palmitate, respectively. Cells 263 
were washed twice with PBS and lifted from the surface with trypsin followed by 2 min 264 
incubation at 37ºC. Trypsinization was stopped with 10% FBS containing media and 265 
equal volumes of cell suspension were mixed with 0.4% Trypan blue staining. Trypan 266 
blue positive and negative cells were counted using a Neubauer chamber for adipocytes 267 
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and Countess Automated Cell Counter (Invitrogen) for macrophages. Percentage of 268 
viability was determined normalizing viable cells of each group to viable cells of BSA 269 
GFP group. Statistical significance was assessed using two-way Anova analysis of three 270 
individual experiments (* p<0.05). 271 
 272 
CPT1 activity 273 
Mitochondria-enriched fractions were obtained from cell culture grown in 10-cm2 274 
dishes and CPT1 activity was measured by a radiometric method as described (13). 275 
 276 
Fatty acid oxidation  277 
Total oleate oxidation was measured in 3T3-L1 CARΔ1 adipocytes and RAW 264.7 278 
macrophages grown in 25-cm2 flasks, differentiated, and infected as described above. 279 
The day of the assay cells were washed in KRBH 0.1% BSA, preincubated at 37°C for 280 
30 min in KRBH 1% BSA, and washed again in KRBH 0.1% BSA. Cells were then 281 
incubated for 3 h (3T3-L1 CARΔ1 adipocytes) or 2 h (RAW 264.7 macrophages) at 282 
37°C with fresh KRBH containing 11 mM glucose, 0.8 mM carnitine plus 0.2 mM [1-283 
14C] oleate (Perkin Elmer). Oxidation was measured as described (30). The scintillation 284 
values were normalized to the protein content of each flask. 285 
 286 
TG content  287 
Cells were grown in 12-well plates, differentiated and infected as described above. 288 
After 24 h (3T3-L1 CARΔ1 adipocytes) or 18 h (RAW 264.7 macrophages) of FA 289 
treatment, cells were collected for lipid extraction following Gesta et al protocol (10) 290 
with minor modifications: after cell lysis with 0.1% SDS, 1/2/0.12 (v/v/v) 291 
methanol/chloroform/0.5M KCl solution was added, the two phases were separated by 292 
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centrifugation and the upper phase was dried with N2. Finally, lipids were resuspended 293 
in 100% isopropanol and TG were quantified using TG Triglyceride kit (Sigma), 294 
according to the manufacturer's instructions. Protein concentrations were used to 295 
normalize sample values. 296 
 297 
Oil Red O staining 298 
RAW 264.7 macrophages grown on coverslips were infected as described above and 299 
incubated with 0.75 mM of palmitate for 18 hours. After this time, cells were rinsed 300 
twice with PBS, fixed in 10% paraformaldehyde for 30 minutes at room temperature 301 
and washed again with PBS. Then, cells were rinsed with 60% isopropanol for 5 min to 302 
facilitate the staining of neutral lipids and stained with filtered Oil Red O working 303 
solution (0.3 % Oil Red O in isopropanol) for 15 min.  After several washes with 304 
distilled water the coverslips were removed and mounted on a drop of mount medium. 305 
The intracellular lipid vesicles stained with Oil Red O were identified by their bright red 306 
color under the microscope. 307 
 308 
Analysis of intracellular protein oxidation 309 
RAW 264.7 macrophages were cultured in 12-well plates and infected as described 310 
before. After FA treatment, cell extracts were prepared and analyzed for protein 311 
oxidative modifications (i.e. carbonyl group content) with OxyBlot Protein Oxidation 312 
Detection kit (Millipore), following the manufacturer's instructions. 313 
 314 
Western blot analysis 315 
3T3-L1 CARΔ1 adipocytes and RAW 264.7 macrophages were cultured in 12-well 316 
plates, differentiated, and infected as described above. Cells were collected in lysis 317 
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buffer (RIPA) and protein concentration was determined using the BCA protein assay 318 
kit (Thermoscientific). Equal amount of protein from whole cell lysates was resolved by 319 
8% SDS-PAGE and transferred to PVDF membranes (Millipore). Signal detection was 320 
carried out with the ECL immunoblotting detection system (GE Healthcare) and the 321 
results were quantitatively analyzed using Image Quant LAS4000 Mini (GE 322 
Healthcare). The following antibodies were used:  CPT1A (1/6,000; (13)), β-actin (I-19) 323 
(1/4,000;Santa Cruz), Akt and pAkt (Ser473) (1/1,000; Cell Signaling), CHOP (GADD 324 
153; 1/200; Santa Cruz) and IRbeta (1/1,000; Santa Cruz). Human fat tissue was 325 
homogenized in RIPA buffer as previously described (34). Protein extracts (10-20 μg) 326 
were loaded, resolved on 10% SDS-PAGE and transferred to Hybond ECL 327 
nitrocellulose membranes. Membranes were stained with 0.15% Ponceau red (Sigma-328 
Aldrich) to ensure equal loading after transfer and then blocked with 5% (w/v) BSA in 329 
TBS buffer with 0.1% Tween 20. Immunoblotting was performed with 1:2000 goat 330 
anti-human CPT1A (Abcam). Blots were incubated with the appropriate IgG-HRP-331 
conjugated secondary antibody. Immunoreactive bands were visualized with an ECL-332 
plus reagent kit (GE Healthcare). Optical densities of the immunoreactive bands were 333 
measured using Image J analysis software. 334 
 335 
Analysis of mRNA expression by quantitative real-time PCR 336 
Total RNA was extracted from cultured cells grown in 12-well plates using Illustra 337 
MiniRNA Spin kit (GE Healthcare) and cDNA was obtained using Transcriptor First 338 
Strand cDNA Synthesis kit (Roche). Quantitative real-time PCR was performed using 339 
SYBR Green PCR Master Mix Reagent Kit (Life Technologies). Levels of mRNA were 340 
normalized to those of β-actin and expressed as fold change. Forward/reverse primers 341 
for several used genes (other sequences are available upon request): 342 
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 343 
 FORWARD REVERSE 
β-ACTIN 5'- AGGTGACAGCATTGCTTCTG- 3’ 5'- GCTGCCTCAACACCTCAAC-3’ 
CHOP 5´-CCCTGCCTTTCACCTTGG- 3’ 5´-CCGCTCGTTCTCCTGCTC- 3’ 
CPT1A* 5'- GCAGCAGATGCAGCAGATCC- 3’ 5'-TCAGGATCCTCCTCTCTGTATCCC3’ 
EDEM 5'-AAGCCCTCTGGAACTTGCG- 3’ 5'-AACCCAATGGCCTGTCTGG- 3’ 
GRP78 5´-ACTTGGGGACCACCTATTCCT- 3’ 5´-ATCGCCAATCAGACGCTCC- 3’ 
IL-1β 5'- GCCCATCCTCTGTGACTCAT- 3’ 5'- AGGCCACAGGTATTTTGTCG- 3’ 
MCP-1 5'- TCCCAATGAGTAGGCTGGAG-3’ 5'- AAGTGCTTGAGGTGGTTGTG- 3’ 
PDI 5'-ACCTGCTGGTGGAGTTCTATG- 3’ 5'-CGGCAGCTTTGGCATACT- 3’ 
TLR-4 5'- GGACTCTGATCATGGCACTG- 3’ 5'- CTGATCCATGCATTGGTAGGT- 3’ 
TNF-α 5'-ACGGCATGGATCTCAAAAGAC-3’ 5'-AGATAGCAAATCGGCTGAACG- 3’ 
* Recognizes both CPT1A and CPT1AM 344 
400-500mg frozen human adipose tissue was homogenized with an Ultra-Turrax 345 
8 (Ika). Total RNA from adipose biopsies, stromal-vascular fractions (SVF) and isolated 346 
adipocytes were extracted by using RNeasy Lipid Tissue Midi Kit (QIAGEN Science) 347 
following the manufacturer’s instructions and total RNA was treated with 55 U RNase-348 
free DNase (QIAGEN) to avoid contamination with genomic DNA. Between 0.2 and 1 349 
µg of total RNA was reverse-transcribed to cDNA using TaqMan Reverse Transcription 350 
reagents (Applied Biosystems), and subsequently diluted with nuclease-free water 351 
(Sigma) to 20 ng/µl cDNA. For adipose tissue gene expression analysis a real-time 352 
quantitative PCR was performed, with duplicates, on a 7900HT Fast Real-Time PCR 353 
System using commercial Taqman Assays (Applied Biosystems). SDS software 2.3 and 354 
RQ Manager 1.2 (Applied Biosystems) were used to analyse the results with the 355 
comparative threshold cycle (Ct) method (2∆∆Ct). Ct values for each sample were 356 
normalized with an optimal reference gene (cyclophilin), after testing three additional 357 
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housekeeping genes: β-actin and RNA 18S. A panel of genes involved in the adipocyte 358 
differentiation and metabolism was selected in the study of CPT1A gene expression:  359 
GEN  SIMBOL GENE DENOMINATION ASSAI ID
ACC1  (acetyl-coenzyme carboxylase 1) ACACA Hs00167385_m1
PCK2 (phosphoenolpyruvate carboxykinase 2) Hs00388934_m1
PPARα  (peroxisome proliferator-activated receptor α) Hs00231882_m1 
PPARγ  (peroxisome proliferator-activated receptor λ) Hs00234592_m1 
AGPAT3  (1-acyl-sn-glycerol-3-phosphate acyltransferase gamma / LPAAT-g1) Hs00987571_m1 
AGPAT4  (1-acyl-sn-glycerol-3-phosphate acyltransferase / LPAAT-d) Hs00220031_m1 
AGPAT5  (1-acyl-sn-glycerol-3-phosphate acyltransferase / LPAAT-e) Hs00218010_m1 
AGPAT9  (1-acylglycerol-3-phosphate O-acyltransferase 9/ LPAAT-
theta) 
Hs00262010_m1
CDS1  (phosphatidate cytidylyltransferase) Hs00181633_m1
PCYT1A  (choline-phosphate cytidylyltransferase) Hs00192339_m1
PCYT2 (ethanolamine-phosphate cytidylyltransferase Hs00161098_m1
PDE3B  (phosphodiesterase type 3) Hs01057215_m1
FDFT1  (farnesyl-diphosphate farnesyltransferase 1) Hs00926054_m1
SREBF1 (sterol regulatory element binding transcription factor 1) Hs01088691_m1
BCL2  (B-cell CLL/lymphoma 2) Hs99999018_m1
CD163 Macrophage and monocyte marker Hs01016661 _m1
CPT1A  (carnitine palmitoyltransferase 1A) Hs00912676_m1
 360 
Cytokines measurement in culture media 361 
Cytokines protein levels in culture media of 3T3-L1 CARΔ1 adipocytes and RAW 362 
264.7 macrophages were measured by Luminex technology with a MILLIPLEX 363 
Analyzer Luminex 200x Ponenet System (MCYTOMAG-70K-08 Mouse Cytokine 364 
MAGNETIC Kit; Merck Millipore). 365 
  366 
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 367 
Analysis of cellular redox status 368 
To detect ROS (superoxide) formation, MitoSOX Red (M36008 - Life Techonologies) 369 
fluorescence was measured by flow cytometry. RAW 264 cells were infected with 100 370 
moi AdCPT1AM (or AdGFP as control) for 48h; then 16h prior to ROS measurement, 371 
macrophages were treated with 0.75 mM palmitate BSA-conjugated (or with BSA as 372 
control). Medium was removed and cells were incubated for 30 min with PBS 373 
containing 5 μM MitoSOX Red. The labeled macrophages were washed three times 374 
with HBSS/Ca/Mg, pelleted, resuspended in 300 μl HBSS/Ca/Mg and fixed by adding 375 
1.2 ml absolute ethanol and keeping them at -20ºC for 5 minutes. Cells were pelleted 376 
again and resuspended in HBSS/Ca/Mg containing 3 μM DAPI, to mark their nuclei. 377 
Then macrophages were analyzed by flow cytometry (Gallios Cytometer - Beckman 378 
Coulter). The fluorescence intensity of MitoSOX Red was measured using excitation at 379 
510 nm and emission at 580 nm. 380 
 381 
Statistical analysis 382 
Data are expressed as the mean ± SEM and analyzed statistically using Student’s t-test 383 
(column analysis) or two-way ANOVA (grouped analysis). All figures and statistical 384 
analyses were generated using GraphPad Prism 6. P<0.05 was considered statistically 385 
significant. For human data statistical analyses were performed with SPSS 12.0 (SPSS). 386 
Results are expressed as mean ± SD. The non-normally distributed variables were 387 
represented as the median (interquartile range). Categorical variables were reported by 388 
number (percentages). Student’s t test analysis was used to compare the mean value of 389 
normally distributed continuous variables. Variables with a non-Gaussian distribution 390 
were analyzed by using non-parametric test (Kruskal-Wallis, or Mann-Whitney test for 391 
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independent samples or Wilcoxon test for related samples when necessary). 392 
Associations between continuous variables are sought by correlation analyses. Finally a 393 
stepwise multiple linear regression analysis is performed to determine independent 394 
variables associated with CPT1A gene expression levels in SAT and VAT depot. 395 
Results are expressed as unstandardized coefficient (B), and 95% confidence interval 396 
for B (95%CI(B)). Differences are considered significant if a computed two-tailed 397 
probability value (P) is < 0.05. 398 
 399 
400 
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RESULTS 401 
CPT1A expression pattern in human adipose tissue from obese and diabetic 402 
patients 403 
Visceral and subcutaneous adipose tissue (VAT and SAT, respectively) were 404 
analyzed from both an obesity cohort (lean, overweight and obese patients) and a T2D 405 
cohort (control and T2D patients). Tables 1 and 2 show the phenotypic and metabolic 406 
characteristics and CPT1A expression levels of the subjects. No differences in CPT1A 407 
gene expression levels either in SAT or in VAT depots were observed when comparing 408 
with the non-obese or the non-diabetic counterparts (Fig. 1A and B; Tables 1 and 2). 409 
However, in the obesity cohort, CPT1A mRNA expression was significantly higher in 410 
lean and overweight VAT than in SAT (Fig. 1A). This difference was lost in the obese 411 
patients. These results were corroborated by Western blot with human adipose tissue of 412 
several lean and obese individuals (Fig. 1C and D, P=0.015). Similar results were 413 
obtained in the T2D cohort, where control subjects showed significantly higher CPT1A 414 
mRNA levels in VAT vs. SAT (Fig. 1B). However, this difference disappeared in T2D 415 
patients. Despite T2D patients showed a trend to express higher CPT1A levels in SAT 416 
and VAT compared to controls (on the opposite than in the obese subjects) this 417 
difference was non-significant. Since CPT1B isoform is also expressed in human 418 
adipose tissue we analyzed CPT1B mRNA (Fig. 1E and F) and protein (data not shown) 419 
levels in human VAT and SAT of the obesity and the T2D cohort. No differences were 420 
seen among the groups. 421 
In order to establish the main relationship between CPT1A gene expression and 422 
key adipocyte genes involved in differentiation and metabolic pathways we explored a 423 
panel of genes (listed in Material and Methods) both in SAT and VAT depots of the 424 
obesity cohort. Results are shown from those genes that changed the most (up or down) 425 
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(Tables 3 and 4). Simple association analysis showed an inverse correlation between 426 
CPT1A and PPAR-γ in SAT (r= -0.38, P= 0.002) (Table 3). Positive CPT1A correlation 427 
both in VAT and SAT was found with AGPAT5 (phospholipid biosynthesis), SREBF1 428 
(glucose and lipid metabolism), BCL2 (anti-apoptosis) and CD163 (macrophage 429 
marker) (Table 3).  430 
To study the main determinants of CPT1A gene expression levels, a stepwise 431 
multiple regression analysis was performed, including the above-mentioned bivariate 432 
associations and confounding factors such as BMI, age and gender. This model showed 433 
that SAT CPT1A was positively associated with AGPAT5, SREBF1 and CD163 and 434 
that VAT CPT1A was positively correlated with SREBF1 and CD163 and negatively 435 
with age and PPAR-γ (Table 4). The inverse relationship between CPT1A and PPAR-γ 436 
was corroborated with the human adipocyte cell line SGBS. CPT1A mRNA expression 437 
dropped to a new steady state in adipocytes that was 11% of its expression in fibroblasts 438 
(data not shown). 439 
 440 
CPT1A is highly expressed in human adipose tissue macrophages 441 
To determine the cellular distribution of CPT1A gene and protein in human 442 
adipose tissue biopsies, we performed qRT-PCR and immunostaining analysis on both 443 
adipose and stromal-vascular fraction (SVF). CPT1A mRNA levels were 42.6-, and 444 
43.4-fold increased in the SVF compared to mature adipocytes in both human SAT 445 
(P<0.05) and VAT (P<0.05), respectively (Fig. 2A). Immunohistological examination 446 
of SAT from obese subjects revealed CPT1A+ cells mostly in the SVF (Fig. 2B). 447 
Immunofluorescence detection showed a bright staining pattern in cells resembling 448 
adipose tissue macrophages. Co-staining analysis using CPT1A and CD68 (a 449 
macrophage marker) antibodies confirmed the expression of CPT1A in macrophages 450 
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(Fig. 2C). Macrophages seem to localize forming the so-called “crown-like structures” 451 
surrounding the adipocytes.  452 
 453 
CPT1AM-expressing adipocytes show enhanced FAO and reduced TG content 454 
To further study the role of CPT1A in adipocytes and macrophages we decided 455 
to continue with in vitro studies. Since 3T3-L1 adipocytes are inefficiently infected with 456 
adenovirus we decided to use the high-infection efficiency white adipocyte cell culture 457 
line, 3T3-L1 CARΔ1 adipocytes (31) (Fig. 3A). Cells were transduced for the first time 458 
with adenoviruses carrying the CPT1AM gene or GFP as a control. Interestingly, 459 
CPT1AM-expressing adipocytes were partially protected from palmitate induced cell 460 
death (Fig. 3C). 461 
CPT1A mRNA, protein and activity levels were increased in CPT1AM-462 
expressing adipocytes compared to GFP control cells (Fig. 4A-C). CPT1AM-expressing 463 
adipocytes retained most of the CPT1 activity after incubation with the CPT1A inhibitor 464 
malonyl-CoA (Fig. 4C). FAO rate was concordantly enhanced (1.37-fold increase, 465 
P<0.05) in CPT1AM-expressing adipocytes (Fig. 4D). FA undergoing β-oxidation yield 466 
acetyl-CoA moieties that have two main possible fates: (1) complete oxidation to CO2 467 
and ATP production, or (2) conversion to ketone bodies (mainly in the liver). Here, total 468 
FAO rate was calculated as the sum of acid soluble products plus CO2 oxidation. 469 
CPT1AM expression blocked the palmitate-induced increase in TG content (Fig. 4E).  470 
 471 
Enhanced adipocyte FAO improves insulin sensitivity and reduces inflammation 472 
We examined the effect of increased FAO on insulin sensitivity and 473 
inflammatory responses in 3T3-L1 CARΔ1 adipocytes infected with AdCPT1AM. 474 
Palmitate-induced decrease in insulin-stimulated Akt phosphorylation and insulin 475 
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receptor beta (IRbeta) protein levels was partially restored in CPT1AM-expressing 476 
adipocytes (Fig. 4F-H). Palmitate-induced increase of proinflammatory markers (IL-1β, 477 
MCP-1 and IL-1α) mRNA and protein levels was blunted in CPT1AM-expressing 478 
adipocytes (Fig. 4I-K). Several palmitate concentrations and times of incubation were 479 
used to better fit the different dose- and time-response of the cytokines and parameters 480 
measured. Consistent with previous studies (9, 11), palmitate incubation raised 481 
cytokines expression by 2-3-fold. 482 
 483 
Increased FAO in CPT1AM-expressing macrophages protects from palmitate-484 
induced TG accumulation 485 
Since CPT1A was highly expressed in the SVF, and particularly in 486 
macrophages, of human adipose tissue we decided to further analyze the effect of an 487 
increased FAO on cultured macrophages. RAW 264.7 macrophages were efficiently 488 
infected with AdCPT1AM (Fig. 3B). CPT1AM-expressing macrophages were protected 489 
from palmitate induced cell death (Fig. 3D). CPT1AM-expressing macrophages showed 490 
a 2.4-fold (P<0.01) increase in CPT1A mRNA levels, 6.6-fold (P<0.01) increase in 491 
protein levels and 2.2-fold (P<0.05) increase in activity levels (Fig. 5A-C). In addition, 492 
we showed that malonyl-CoA did not inhibit CPT1 activity in CPT1AM-expressing 493 
macrophages (Fig. 5C). CPT1AM-expressing macrophages showed a 1.5-fold increase 494 
in FAO rate compared to GFP control cells (Fig. 5D, P<0.05) and a total restoration in 495 
palmitate-induced enhancement of TG content (Fig. 5E and F).  496 
 497 
Enhanced macrophage FAO reduced inflammation, ER stress and ROS damage 498 
Palmitate-induced increase in proinflammatory cytokines (TNF-α, MCP-1, IL-499 
1β, TLR-4 and IL-12p40) and ER stress markers (CHOP, GRP78, PDI and EDEM) 500 
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mRNA and protein levels was blunted in CPT1AM-expressing macrophages (Fig. 6A, 501 
B, D and E)). Consistent with previous studies (18, 47, 48), palmitate incubation raised 502 
cytokines expression by 2-3-fold. No differences were seen in anti-inflammatory 503 
markers such as IL-10, Mgl-1 and IL-4 in CPT1AM-expressing cells incubated with or 504 
without palmitate (Fig. 6C). Incubation with etomoxir, a permanent inhibitor of CPT1A, 505 
counteracted the reduction of MCP-1 expression seen in CPT1AM-expressing cells 506 
incubated with palmitate (data not shown). We also studied the effect of enhanced FAO 507 
in RAW 264.7 macrophages on palmitate-induced ROS damage by protein carbonyl 508 
content analysis. Palmitate-induced ROS damage was reduced in CPT1AM-expressing 509 
macrophages (Fig. 6F). This reduction was not detected when ROS (superoxide) was 510 
directly measured by using the MitoSOX Red probe (Fig. 6G). 511 
512 
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DISCUSSION 513 
The obesity epidemic has put a spotlight on the adipose tissue as a key player in 514 
obesity-induced insulin resistance (38). Obese individuals and those with T2D have 515 
lower FAO rates (17, 19, 37). Although these data were reported in skeletal muscle, we 516 
expected to see reduced CPT1A expression levels in the adipose tissue of both obese 517 
and T2D patients. However, no differences were seen in CPT1A mRNA expression 518 
between the obese or T2D and their respective controls either in VAT or in SAT. Other 519 
authors have reported a decrease in VAT CPT1 mRNA and protein levels in obese 520 
individuals (20). However, the authors did not specify which of the CPT1 isoforms was 521 
measured in VAT: CPT1A or CPT1B. We showed that CPT1A expression is higher in 522 
adipose tissue macrophages than in mature adipocytes. Since the obese adipose tissue 523 
has higher infiltration of immune cells such as macrophages, we postulate that the 524 
putative decrement of CPT1A expression in obese individuals could be compensated by 525 
increased expression from the infiltrated macrophages and thus, no differences are seen 526 
between the groups. CPT1B isoform is also expressed in human adipose tissue and it 527 
has been shown to raise FAO in metabolic tissues such as skeletal muscle (3). Thus, we 528 
measured mRNA and protein levels in the obese and T2D cohorts. However, no 529 
differences were seen among the groups indicating that CPT1B expression is not 530 
changed by obesity and T2D. 531 
 We found that in insulin sensitive individuals (control and overweight patients 532 
from the obese cohort and control patients from the T2D cohort) CPT1A mRNA 533 
expression was higher in VAT than in SAT. However, no differences between VAT and 534 
SAT were seen in the more insulin-resistant individuals with a more pro-inflammatory 535 
environment: obese and T2D patients. A similar phenomenon was described for T 536 
regulatory cells, described to have anti-inflammatory properties and to improve obesity-537 
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induced insulin resistance (7). The authors reported that VAT and SAT of healthy 538 
individuals had similar low numbers of T regulatory cells at birth, with a progressive 539 
accumulation over time in the VAT, though not the SAT. Our results suggest a CPT1A 540 
expression balance between SAT and VAT depots that may be disturbed in obese and 541 
T2D patients. The difference in CPT1A expression between these two fat depots is 542 
potentially crucial, given the association of VAT, but not SAT with insulin resistance 543 
(1, 52). It might indicate, in healthy individuals, a potential protective role of CPT1A in 544 
the more insulin-resistant associated VAT. 545 
Gene expression analysis revealed a negative association between CPT1A and 546 
the adipocyte marker of differentiation PPAR-γ. This is consistent with the fact that 547 
while white adipocytes mature they shift their lipid preferences to storage rather than 548 
oxidation. Aging was associated with reduced CPT1A expression in VAT. This might 549 
reflect a potential protective role of CPT1A expression in VAT, which is lost with age. 550 
Considering that VAT accretion is a hallmark of aging and especially, it is a stronger 551 
risk factor for comorbidities and mortality (23), we speculate a favorable role of 552 
enhanced CPT1A expression in age metabolic decline and related pathological 553 
conditions. Positive correlation both in VAT and SAT CPT1A was found with 554 
AGPAT5, SREBF1, BCL2 and CD163. These results may indicate a potential role of 555 
CPT1A in lipid biosynthesis processes (AGPAT5), glucose and lipid metabolism 556 
(SREBF1) and in protecting adipose tissue from apoptosis (BCL2). The positive 557 
association between CPT1A and CD163 (macrophage marker) was not surprising given 558 
the higher CPT1A expression in macrophages than in adipocytes (Fig. 2). 559 
We are aware that many of the above mentioned associations may be secondary 560 
to obesity or T2D and that no causal relationship may be inferred with this study design. 561 
In order to prove the causality of some of these observations we performed in vitro 562 
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studies directly targeting adipocytes and macrophages to burn off the excess lipids 563 
through an increase in FAO. We used the high-infection efficiency adipocyte cell line, 564 
3T3-L1 CARΔ1 (31), to express for the first time CPT1AM through adenoviral 565 
infection. Noteworthy, white adipocytes are designed to store lipids rather than to 566 
oxidize them. Thus, CPT1 activity in WAT is lower than in other tissues (6). However, 567 
CPT1AM-expressing adipocytes showed a 4.3-fold increase in CPT1 activity that was 568 
not inhibited despite incubation with high concentrations of malonyl-CoA. Since 569 
increased lipid accumulation, inflammation, ER stress and ROS-induced protein 570 
damage trigger metabolic diseases we decided to measure TG content, inflammation, 571 
ER stress and ROS damage as important mechanisms that could explain the potential 572 
protective effect of CPT1AM expression. Enhanced FAO led to complete restoration of 573 
TG content, improved insulin signaling (measured as pAkt), increased IRbeta 574 
expression and cell viability and reduced inflammation in palmitate-incubated 575 
CPT1AM-expressing adipocytes. CPT1AM-expressing adipocytes showed a general 576 
improvement in lipid-induced derangements as a consequence of increased FA flux 577 
through mitochondria. However, enhanced FA flux in the absence of a concomitant 578 
dissipation of FAO metabolites has been associated with increased ROS damage (35) 579 
and inflammation (8, 21, 43). Interestingly, while no differences were seen in ER or 580 
oxidative stress (data not shown), CPT1AM-expressing adipocytes showed a significant 581 
decrease in proinflammatory mediators such as IL-1β and MCP-1. The favorable role of 582 
CPT1A in adipocytes to attenuate FA evoked insulin resistance and inflammation has 583 
been also described to act via suppression of JNK (9). These results suggest that factors 584 
other than a FAO increase per se are responsible for ROS production and inflammation. 585 
Accumulation of toxic substances (diacylglycerol or ceramides) (49), hypoxia (15), as 586 
well as cytokines (42) might participate in the induction of ROS damage and the 587 
 28
inflammatory state. Several researchers have demonstrated that enhanced FAO through 588 
CPT1A or CPT1AM expression results in a decrease in relevant lipid mediators 589 
involved in inflammation and insulin resistance such as diacylglycerol, intracellular 590 
NEFAs (non-esterified FA), free FA, ceramides and TG (3, 9, 13, 26, 29, 40, 45). While 591 
some authors (3) didn’t see changes in skeletal muscle acylcarnitines’ profile our group 592 
has shown an increase in several acylcarnitines in CPT1AM-expressing neurons (25). 593 
FA undergoing β-oxidation yield acetyl-CoA moieties that have two main 594 
possible fates: (1) entry to the Krebs cycle for complete oxidation and ATP production, 595 
or (2) conversion to ketone bodies (mainly in the liver). We observed increased FAO to 596 
CO2 and acid soluble products in CPT1AM-expressing adipocytes and macrophages. 597 
CPT1AM expression in liver has been shown to enhance ATP and ketone bodies 598 
production with no changes in glucose oxidation (29), (13). Altogether, this indicates a 599 
metabolic rate switch towards FA.  600 
 Monocytes were the first immune cells reported to infiltrate obese adipose 601 
tissue, differentiate to macrophages, produce inflammatory cytokines and trigger insulin 602 
resistance (56, 57). Thus, we examined whether CPT1AM expression could play a 603 
protective role in obesity-induced macrophage derangements. We found that, in human 604 
WAT, CPT1A is highly expressed in SVF compared to adipocytes. This happened both 605 
in human VAT and SAT. A closer histological and immunofluorescence examination 606 
showed that macrophages present in the adipose tissue expressed CPT1A. This does not 607 
rule out CPT1A expression in other immune cells also present in the adipose tissue such 608 
as T and B cells, T regulatory cells, and mast cells.  609 
Given the high CPT1A expression in human adipose tissue macrophages, we 610 
decided to study the effect of CPT1AM in RAW 264.7 macrophages. A permanently 611 
enhanced FAO rate in CPT1AM-expressing macrophages led to a complete restoration 612 
 29
of palmitate-induced increase in TG content, and a decrease in inflammation, ER and 613 
oxidative stress without affecting cell viability. Recent data show that FAO is capable 614 
of regulating the degree of acyl chain saturation in ER phospholipids (28). Since 615 
increasing the degree of saturation in ER phospholipids has been described to directly 616 
activate ER stress and inflammation (28) this might provide a mechanistic link to how 617 
FAO alleviates ER stress under palmitate loading. Thus, enhancing CPT1A expression 618 
in macrophages may be a potential approach to fight against obesity-induced disorders. 619 
 In conclusion, we have shown that CPT1A expression was higher in human 620 
adipose tissue macrophages than in mature adipocytes and that it was differentially 621 
expressed in VAT vs. SAT. Further in vitro studies demonstrated that an increase in 622 
FAO in lipid-treated adipocytes and macrophages reduced TG content and 623 
inflammatory levels, improved insulin sensitivity in adipocytes, and reduced ER stress 624 
and ROS damage in macrophages. Adipocyte specific knockout or transgenic animal 625 
models for CPT1A would be especially relevant to elucidate its potential protection 626 
against obesity-induced insulin resistance in vivo. Our data support the hypothesis that 627 
pharmacological or genetic strategies to enhance FAO may be beneficial for the 628 
treatment of chronic inflammatory pathologies such as obesity and T2D. 629 
630 
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Tables 851 
Table 1. Clinical, analytical and CPT1A gene expression analysis of the obesity cohort. 852 
BMI: Body mass index; sIL-6: soluble Interleukine-6; SBP: systolic blood pressure; 853 
DBP: Diastolic blood pressure. Values are expressed as mean ± SD or median 854 
(interquartile range) for a non-Gaussian distributed variables. Differences vs. Lean: 855 
*P<0.001; ¶P<0.05. Differences vs. Overweight: #P<0.001; §P<0.05. †P<0.05 SAT vs. 856 
VAT expression. 857 
 858 
Table 2. Clinical, analytical and CPT1A gene expression analysis of the T2D cohort. 859 
BMI: Body mass index; sIL-6: soluble Interleukine-6; SBP: systolic blood pressure; 860 
DBP: Diastolic blood pressure. Values are expressed as mean ± SD or median 861 
(interquartile range) for a non-Gaussian distributed variables. Differences vs. controls: 862 
*P<0.001; ¶P<0.05. Differences between SAT and VAT in the same group: †P=0.03. 863 
 864 
Table 3. Bivariate correlation analysis of CPT1A gene expression levels with several 865 
genes in human VAT and SAT of the obesity cohort. PPAR-γ, Peroxisome proliferator-866 
activated receptor gamma; AGPAT5, 1-acylglycerol-3-phosphate O-acyltransferase 5; 867 
SREBF1, sterol regulatory element binding transcription factor 1; BCL2, B-cell 868 
CLL/lymphoma 2; CD163, macrophage and monocyte marker; p<0.005 for all 869 
correlations. 870 
 871 
Table 4. Multiple regression analysis for CPT1A in VAT and SAT as dependent 872 
variable in the obesity cohort. Independent variables included in the model: age, gender, 873 
body mass index (BMI), peroxisome proliferator-activated receptor alpha (PPAR-α), 874 
peroxisome proliferator-activated receptor gamma (PPAR-γ), 1-acylglycerol-3-875 
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phosphate O-acyltransferase 5 (AGPAT5), sterol regulatory element binding 876 
transcription factor 1 (SREBF1), B-cell CLL/lymphoma 2 (BCL2) and macrophage and 877 
monocyte marker (CD163) gene expression levels. β st: standardized beta coefficient. 878 
CI: Confidence Interval. 879 
  880 
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Figure legends 881 
Fig. 1. CPT1 gene and protein expression in human adipose tissue. (A, B) CPT1A 882 
relative mRNA levels in human VAT and SAT of the obesity (A) or the T2D (B) 883 
cohort. Number of individuals: 19 lean, 28 overweight, 15 obese, 36 control and 11 884 
T2D (See Table 1 and 2 for more details). (C, D) CPT1A protein levels in human VAT 885 
and SAT of seven lean individuals (P1-P7) (C) and three obese individuals (D). (E, F) 886 
CPT1B relative mRNA levels in human VAT and SAT of the obesity (E) or the T2D 887 
(F) cohort. *P<0.05. 888 
 889 
Fig. 2. CPT1A is highly expressed in human adipose tissue macrophages. (A) CPT1A 890 
mRNA levels in both adipose (AD) and stromal-vascular fraction (SVF) of human VAT 891 
and SAT. n=4. *P<0.05. (B) Immunohistochemical detection of CPT1A (brown) in 892 
SAT of obese subjects. (C) Immunofluorescence staining of CPT1A (red) and CD68 893 
(green) proteins in SAT of obese individuals. The counterstaining of nuclei (DAPI) is 894 
shown in blue. Images are representative of adipose tissue preparations collected from 895 
three subjects.  896 
 897 
Fig. 3. Adenovirus infection efficiency and viability in 3T3-L1 CARΔ1 adipocytes and 898 
RAW 264.7 macrophages. Images were taken from (A) AdGFP-infected 3T3-L1 899 
CARΔ1 adipocytes (50% infection) or (B) RAW 264.7 macrophages (70% infection) 900 
48h or 72h after the infection, respectively. (C, D) Cell viability of (C) 3T3-L1 CARΔ1 901 
adipocytes or (D) RAW 264.7 macrophages infected with AdGFP or AdCPT1AM and 902 
incubated for 24h with 1mM or 0.3mM palmitate (PA), respectively. 903 
 904 
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Fig. 4 Enhanced FAO in 3T3-L1 CARΔ1 adipocytes improves lipid-induced TG 905 
accumulation, insulin sensitivity and inflammation. Relative CPT1A mRNA expression 906 
(A) and protein levels (B) in AdGFP- or AdCPT1AM-infected 3T3-L1 CARΔ1 907 
adipocytes. (C) CPT1 activity from mitochondria-enriched cell fractions incubated (or 908 
not) with 100 μM malonyl-CoA. (D) Total FAO rate represented as the sum of acid 909 
soluble products plus CO2 oxidation. (E) TG content of adipocytes treated for 24 h with 910 
1mM palmitate (PA). (F) Insulin signaling in GFP- and CPT1AM-expressing 911 
adipocytes incubated with 0.3mM PA for 24 h as indicated by Western blotting of 912 
insulin-induced Akt phosphorylation (pAkt) and IRbeta. (G) Quantification of pAkt 913 
normalized by total Akt (fold change of arbitrary units, A.U.). (H) Quantification of 914 
IRbeta normalized by β-actin. (I, J) Relative mRNA expression from GFP- or CPT1A-915 
expressing adipocytes incubated with 1mM PA for 24 h. (K) Protein levels of IL-1α in 916 
the culture media of GFP- or CPT1A-expressing adipocytes incubated with 1mM PA 917 
for 6 h. Shown representative experiments out of 3. n=3-6. *P<0.05. 918 
 919 
Fig. 5. Enhanced FAO and reduced TG content in CPT1AM-expressing RAW 264.7 920 
macrophages. Relative CPT1A mRNA expression (A) and protein levels (B) in AdGFP- 921 
or AdCPT1AM-infected macrophages. (C) CPT1 activity from mitochondria-enriched 922 
cell fractions incubated (or not) with 100 μM malonyl-CoA. (D) Total FAO rate 923 
measured as the sum of acid soluble products plus CO2 oxidation. (E) TG content and 924 
(F) Oil Red O staining of macrophages treated for 18 h with 0.75 mM palmitate (PA). 925 
Shown representative experiments out of 3. n=3-6. *P<0.05. 926 
 927 
Fig. 6. CPT1AM expression reduced inflammation, ER stress and ROS damage in 928 
RAW 264.7 macrophages. (A, C, D) Relative mRNA gene expression from 929 
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macrophages incubated with 0.5 mM palmitate (PA) for 8 h (TNF-α and MCP-1) or 0.3 930 
mM PA for 24 h (IL-10, Mgl-1, IL-4, IL-1β, TLR-4, CHOP, GRP78, PDI and EDEM). 931 
(B) Protein levels of IL-12p40 in the culture media of macrophages incubated with 0.3 932 
mM PA for 24 h. (E) CHOP protein levels and quantification in macrophages incubated 933 
with 0.5 mM PA for 8 h (F) Protein carbonyl content analysis and quantification in 934 
macrophages incubated with 0.75 mM PA for 18 h. (G) Measurement of ROS 935 
(superoxide) using the MitoSOX Red probe. Shown representative experiments out of 936 
3. n=3-4 *P<0.05. 937 
 938 
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